Publications by authors named "Chander Sehgal"

Claim this Profile
F
Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Sam Salek, Sarah Lussier Hoskyn, Jeffrey Roy Johns, Nicola Allen, Chander Sehgal

Front Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Sam M Salek, Sarah Lussier Hoskyn, Jeffrey Johns, Nicola Allen, Chander Sehgal

Front Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Ghayath Janoudi, William Amegatse, Brendan McIntosh, Chander Sehgal, Trevor Richter

Orphanet J Rare Dis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study.
Nicola Allen, Stuart R Walker, Lawrence Liberti, Chander Sehgal, M Sam Salek

CMAJ Open· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.
Malek B Hannouf, Chander Sehgal, Jeffrey Q Cao, Joseph D Mocanu, Eric Winquist

PLoS One· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis